T cell

Showing 8 posts of 8 posts found.


Cardiff University team discovers new method of killing cancers

January 21, 2020
Manufacturing and Production Cancer, Cancer cures, Cancerous, Cardiff University, T cell, cells, immune system, immunity, t-cell

A team at Cardiff University have discovered a new part of the human immune system that could be harnessed to …

T cells found to ‘acquire knowledge’ to take fight to metastatic cancer

May 17, 2017
Research and Development Cancer, T cell, immunotherapy

T cells are widely known as being crucial in the fight against cancer within the body but little was known, …


Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial

August 4, 2016
Research and Development Adaptimmune, T cell, oncology, t-cell

Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …


Targeted cancer therapies can suppress T cell immune responses, study finds

March 23, 2016
Research and Development T cell, anti-cancer drugs, immunosuppresive, superagonist, wistar institute

Researchers at the Wistar Institute have developed a new method whereby targeted cancer therapies can provide appropriate therapeutics without supressing …

Merck Serono image

Merck Serono in $826m immuno-oncology deal

March 31, 2015
Research and Development, Sales and Marketing Intrexon, Merck, Merck Serono, T cell, biopharma, cart, immuno-oncology, t-cell

Merck Serono has announced a significant deal with Intrexon to develop and bring new cancer treatments to market. The German …

T cell image

UK makes £30m investment in T-Cell cancer therapy

January 22, 2015
Research and Development, Sales and Marketing Autolus, Cancer, London, T cell, UK, government, oncology, syncona

The UK is making a £30 million R&D investment into a promising new type of cancer treatment and is to …

Adaptimmune wins fund payout

March 26, 2014
Research and Development, Sales and Marketing Adaptimmune, Cancer, T cell, biomedical, noble, sme

Biotech firm Adaptimmune has been awarded £2.1 million from the UK government’s Biomedical Catalyst Fund, which was set up to …

Tolerx to collaborate on first-in-class cancer antibody

December 2, 2010
Research and Development Cancer, T cell, Torelx, monoclonal antibody

US biopharma company Tolerx is to work with a non-profit cancer research fund to develop its first in class antibody …

Latest content